Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2023-185857

Published: 2023

Journal Articles

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song, Jin Seok Kim, CS Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Wei-Ying Jen, Xinhua Li, Yogesh Mahadev Pokharkar, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2023-184723

Published: 2023

Journal Articles

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Shinsuke Iida, Asuka Mori, Chika Sakai, Kenichi Kato, David Bin-Chia Wu, DaeYoung Yu, Shota Nemoto, Yasuho Yamashita, Takuma Shibahara

Blood (2023) 142 (Supplement 1): 6665.

https://doi.org/10.1182/blood-2023-172849

Published: 2023

Journal Articles

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Blood (2022) 140 (Supplement 1): 6902–6904.

https://doi.org/10.1182/blood-2022-168213

Published: 2022

Journal Articles

The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study

Yoshitaka Miyakawa, Kazunori Imada, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Akihito Yonezawa, Shigeki Fujitani, Hiroshi Handa, Tadashi Matsushita, Hidesaku Asakura, Kenji Nishio, Kodai Suzuki, Yasuhiro Hashimoto, Shinobu Ohshima, Sayaka Tahara, Tomoyuki Tanaka, Masanori Matsumoto

Blood (2021) 138 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2021-148427

Published: 2021

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2021-149270

Published: 2021

Journal Articles

Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT

Blood (2021) 138 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2021-147587

Published: 2021

Journal Articles

Prognostic Impacts of Additional Cytogenetic Abnormalities Acquired at the First Relapse in Adult Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission

Hiroaki Shimizu, Junichi Mukae, Naoki Shingai, Takashi Toya, Yuho Najima, Takeshi Kobayashi, Nahoko Hatsumi, Satoru Takada, Hiroshi Handa, Kyoko Haraguchi, Yoshiki Okuyama, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki

Blood (2021) 138 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2021-152621

Published: 2021

Journal Articles

Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2021-149556

Published: 2021

Journal Articles

Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia

Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Blood (2021) 138 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2021-146744

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy

Blood (2021) 138 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2021-151855

Published: 2021

Journal Articles

Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Xinhua Li, Cindy Lin, Jin Seok Kim, MD PhD, Hiroshi Handa, MD PhD, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139019

Published: 2020

Journal Articles

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia

Taro Tochigi, Toshihiro Miyamoto, Kiwamu Hatakeyama, Teppei Sakoda, Daisuke Ishihara, Hidetoshi Irifune, Takahiro Shima, Koji Kato, Takahiro Maeda, Takumi Ito, Hiroshi Handa, Koichi Akashi, Yoshikane Kikushige

Blood (2020) 135 (24): 2146–2158.

https://doi.org/10.1182/blood.2019003749

Published: 2020

Includes: Supplemental data

Journal Articles

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Blood (2019) 134 (Supplement_1): 845.

https://doi.org/10.1182/blood-2019-122802

Published: 2019

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

DNA Polymerases Pol θ/Pol η Involved in Error-Prone DNA Repair Are Highly Expressed in Multiple Myeloma and Upregulated By DNA Damage

Blood (2019) 134 (Supplement_1): 4364.

https://doi.org/10.1182/blood-2019-125163

Published: 2019

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT

Prognostic Impacts of Additional Cytogenetic Abnormalities Acquired at the First Relapse in Adult Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission

Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms

Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy

Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia

Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

DNA Polymerases Pol θ/Pol η Involved in Error-Prone DNA Repair Are Highly Expressed in Multiple Myeloma and Upregulated By DNA Damage

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only